The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives

Sodium glucose cotransporter 2 inhibitors (SGLT2) have been increasingly pursued as a promising target for addressing residual cardiovascular risk. Prior trials demonstrated that SGLT2i not only promotes glucose-lowering, but also improves endothelial dysfunction, adiposity, fluid overload, and insu...

Descripción completa

Detalles Bibliográficos
Autores principales: Barreto, Joaquim, Campos-Staffico, Alessandra M., Nadruz, Wilson, Quinaglia, Thiago, Sposito, Andrei C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Clinical Diabetes and Healthcare
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562622/
https://www.ncbi.nlm.nih.gov/pubmed/37822556
http://dx.doi.org/10.3389/fcdhc.2023.1243530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562622/
https://www.ncbi.nlm.nih.gov/pubmed/37822556
http://dx.doi.org/10.3389/fcdhc.2023.1243530

Ejemplares similares